MUMBAI, India, June 26 /PRNewswire/ -- Lupin Ltd, announced today that
Dr. Raj Kamboj has joined the company as President -- New Chemical Entity
Research. This reflects the Company's commitment to continually strengthen
its team by attracting the best talent globally.

    Raj is an eminent scientist from the world of drug discovery. He is a
PhD from University of Adelaide, Australia & joins Lupin from Xenon
Pharmaceuticals Inc., Vancouver, where he had been working for the past 5
years. He has returned to India after 26 years and brings with him a wide
range of experience in the field of Drug Discovery & Clinical development.
Prior to Xenon, he was working with Allelix, Canada. In both companies Raj
was instrumental in taking the companies from the inception of the drug
discovery group all the way to multiple licensing transactions and
collaborations.

    "We are very excited to have Raj join us as the Chief of our drug
discovery program," Dr. D B Gupta, Chairman, Lupin Ltd. said. "He brings
with him a vast pool of knowledge and experience which will be a great
value add for Lupin's NCE research."

    Lupin is committed to developing new and innovative healthcare products
focusing on unmet needs. It has a pipeline of four Investigational New
Drugs that focus on three different disease areas namely Migraine,
Psoriasis and Tuberculosis. The Company also has pre-clinical programs in
Diabetes and Rheumatoid Arthritis.

    Headquartered in Mumbai, India, Lupin Limited is an innovation led
transnational pharmaceutical company producing a wide range of quality,
affordable generic and branded formulations and APIs for the developed and
developing markets of the world.

    The Company has secured global leadership position in Anti-TB and
Cephalosporins and has a significant presence in the areas of
Cardio-vasculars (prils and statins), Diabetology, Asthma and NSAIDs. The
Company's R&D endeavors have resulted in significant progress in its NCE
program. The Company's foray into Advanced Drug Delivery Systems has
resulted in the development of platform technologies that are being used to
develop value-added generic pharmaceuticals.

    Currently positioned amongst the top six pharmaceutical companies of
India, the Company is committed to achieve sustainable earnings and growth
for all its stakeholders.

    For the financial year ended March 2008, the Lupin's Revenues and
Profit after Tax were Rs.27, 730 million (US$ 694 million) and Rs.4,083
million (US$ 102 million) respectively.



    For further information please contact:

    Lupin Limited:
    Seema Ahuja
    Head, Corporate Communications
    Ph: 9920042046
    Email: seemaahuja@lupinpharma.com

      OR

    Source Strategic Communications Pvt. Ltd.
    Archana Pradhan
    Ph: 9820330505
    Email: archanapradhan@sourcepr.com

Link to this page: